A Screening Study of Potential Carcinogen Biomarkers After Surgical Treatment of Obesity

Ferraz

et al. 2018

Rev. Col. Bras. Cir.

Section: Introductionmentioning

confidence: 99%

Avaliação da qualidade de vida, perda de peso e comorbidades de pacientes submetidos à cirurgia bariátrica

Ferraz

et al. 2018

Rev. Col. Bras. Cir.

International Journal of Surgery Case Reports

“…However, Mackenzie et al, in a cohort study compared 8794 obese post bariatric surgery patients with the same number of patients who did not underwent surgery, and found that, in general, there is a decrease in the cancer development rate in those patients who have undergone the procedure [ 9 , 20 ]. These findings are reinforced by De Siqueira et al, that reported a significant decrease in the expression of potential cancer proteins in obese patients after bariatric surgery [ 21 ].…”

Section: Discussionmentioning

confidence: 69%

Gastrointestinal stromal tumor of the excluded stomach after Roux-en-Y gastric bypass: A case report and literature review

Nascimento

Macedo

Santa‐Cruz

et al. 2020

“…In accordance with the data in mice, mounting data from clinical-based studies suggest TSP-2 as a potent metabolic regulator with multiple beneficial effects on metabolic complications. Increased plasma TSP-2 has been observed in obese patients [ 27 , 28 ], which may contribute to the development of obesity-related metabolic complications and nephropathy of T2DM [ 3 , 25 ]. Nevertheless, the limitation is that we did not distinctly segregate anthropometric, physiological and biochemical parameters with reference to insulin resistance.…”

Section: Discussionmentioning

confidence: 99%

Extracellular status of thrombospondin-2 in type 2 diabetes mellitus and utility as a biomarker in the determination of early diabetic kidney disease

Lin

Zhang

et al. 2023

BMC Nephrol

Objective Thrombospondin-2 (TSP-2) is a multifunctional matricellular glycoprotein correlated with glucose homeostasis, insulin sensitivity, and estimated glomerular filtration rate. Investigation of the association of TSP-2 with type 2 diabetes mellitus (T2DM) and the potential diagnostic value of serum TSP-2 for detecting early diabetic kidney disease (DKD) is needed. Research design and methods An enzyme-linked immunosorbent assay was used for detection serum TSP-2 levels in 494 Chinese T2DM subjects. The protein expression of TSP-2 in the kidney and other tissues were tested by western blotting. Results Serum TSP-2 levels in T2DM subjects were significantly higher than in healthy individuals. Serum TSP-2 correlated positively with triglycerides, serum uric acid, creatinine, platelets, and urinary albumin-to-creatinine ratio (UACR), but negatively with estimated glomerular filtration rate, after adjusting for age, sex, and T2DM duration. Logistic regression analysis demonstrated an independent association between serum TSP-2 and early DKD. Furthermore, the high UACR identified at risk of early DKD increased significantly from 0.78 (95%CI 0.73–0.83) to 0.82 (95%CI 0.77–0.86, p < 0.001) when added to a clinical model consisting of TSP-2 and age. In db/db mice, serum TSP-2 levels were elevated. TSP-2 expression was markedly increased in the kidney tissue compared with that in db/m and m/m mice. Furthermore, serum TSP-2 expression correlated well with UACR in mice. Conclusions TSP-2 is a novel glycoprotein associated with early DKD in patients with T2DM. The paradoxical increase of serum TSP-2 in T2DM individuals may be due to a compensatory response to chronic inflammatory and renal vascular endothelial growth, warranting further investigation.